X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (182) 182
oncology (152) 152
index medicus (144) 144
gw572016 (138) 138
female (129) 129
lapatinib (116) 116
trastuzumab (101) 101
breast cancer (93) 93
breast neoplasms - drug therapy (90) 90
lapatinib gw572016 (88) 88
tyrosine kinase inhibitor (69) 69
receptor, erbb-2 - metabolism (64) 64
cancer (61) 61
receptor, erbb-2 - antagonists & inhibitors (60) 60
growth-factor receptor (54) 54
quinazolines - therapeutic use (54) 54
quinazolines - administration & dosage (53) 53
antineoplastic agents - therapeutic use (52) 52
breast neoplasms - metabolism (52) 52
breast neoplasms - pathology (51) 51
cell line, tumor (51) 51
quinazolines - pharmacology (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
her2 (45) 45
middle aged (44) 44
animals (42) 42
expression (41) 41
pharmacology & pharmacy (41) 41
antibodies, monoclonal, humanized (40) 40
adult (38) 38
antineoplastic agents - pharmacology (38) 38
inhibitor (37) 37
chemotherapy (36) 36
receptor, epidermal growth factor - antagonists & inhibitors (36) 36
adjuvant chemotherapy (35) 35
egfr (35) 35
aged (34) 34
antineoplastic agents (33) 33
care and treatment (33) 33
growth (33) 33
quinazolines - adverse effects (33) 33
skin and connective tissue diseases (32) 32
breast-cancer (31) 31
epidermal growth factor (31) 31
therapy (29) 29
treatment outcome (29) 29
antimitotic agents (28) 28
antitumor-activity (28) 28
phase-ii (28) 28
protein kinase inhibitors - therapeutic use (28) 28
analysis (27) 27
capecitabine (27) 27
cell proliferation - drug effects (27) 27
drug resistance, neoplasm (26) 26
monoclonal-antibody (26) 26
quinazolines - pharmacokinetics (26) 26
erbb2 (25) 25
male (25) 25
mice (25) 25
research (25) 25
tyrosine (25) 25
antibodies, monoclonal - therapeutic use (24) 24
tumors (24) 24
cells (23) 23
drug therapy (23) 23
kinases (23) 23
metastasis (23) 23
signal transduction - drug effects (23) 23
apoptosis (22) 22
protein kinase inhibitors - pharmacology (22) 22
receptor, epidermal growth factor - metabolism (22) 22
breast neoplasms - genetics (21) 21
combination (21) 21
dose-response relationship, drug (21) 21
medicine & public health (21) 21
receptor (21) 21
survival (21) 21
antineoplastic agents - administration & dosage (20) 20
clinical trials as topic (20) 20
neoplasms - drug therapy (20) 20
phase-i (20) 20
receptor, erbb-2 - genetics (20) 20
signal transduction (20) 20
hematology, oncology and palliative medicine (19) 19
antibodies, monoclonal - pharmacology (18) 18
metastatic breast-cancer (18) 18
phase-ii trial (18) 18
phosphorylation (18) 18
protein kinase inhibitors - administration & dosage (18) 18
tyrosine kinases (18) 18
cancer therapies (17) 17
trastuzumab resistance (17) 17
activation (16) 16
antineoplastic agents - adverse effects (16) 16
antineoplastic agents - pharmacokinetics (16) 16
antineoplastic combined chemotherapy protocols - pharmacology (16) 16
article (16) 16
brain metastases (16) 16
drug administration schedule (16) 16
in-vitro (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3366 - 3379
Increased understanding of the molecular events involved in cancer development has led to the identification of a large number of novel targets and, in... 
GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | PHASE-II TRIAL | TRANSFERASE INHIBITOR | ONCOLOGY | TYROSINE KINASE INHIBITOR | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | LAPATINIB GW572016 | TUMOR-GROWTH | MTOR INHIBITOR
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3887 - 3895
Purpose: To investigate the potential of circulating-miRNAs (ct-miRNA) as noninvasive biomarkers to predict the efficacy of single/dual HER2-targeted therapy... 
SURVIVAL | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GROWTH | DOWN-REGULATION | SECONDARY ANALYSIS | RECEPTOR | OPEN-LABEL | LAPATINIB GW572016 | PLUS TRASTUZUMAB | MICRORNA
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2011, Volume 108, Issue 12, pp. 5021 - 5026
Journal Article
by Tsai, CL and Wu, HM and Lin, CY and Lin, YJ and Chao, A and Wang, TH and Hsueh, S and Lai, CH and Wang, HS
PLOS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9
Estrogens and tamoxifen (an antiestrogen) exert their actions by activation of estrogen receptor (ER) through genomic and non-genomic mechanisms and are... 
INDUCED PHOSPHOPROTEIN 1 | BREAST-CANCER | GROWTH-FACTOR RECEPTOR | PROTEIN-COUPLED RECEPTOR | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | 4-HYDROXYTAMOXIFEN | PROLIFERATION | INHIBITOR | LAPATINIB GW572016 | 17-BETA-ESTRADIOL
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2010, Volume 28, Issue 21, pp. E371 - E371
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2011, Volume 29, Issue 2, pp. 166 - 173
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2019, Volume 59, Issue 10, pp. 1379 - 1383
Lapatinib, a tyrosine kinase inhibitor, is approved for the treatment of breast cancer. The literature shows that it is metabolized by CYP3A4 and eliminated... 
ESRD | lapatinib | hemodialysis | pharmacokinetics | renal impairment | KIDNEY-DISEASE | IMPACT | METABOLISM | GW572016 | PHARMACOLOGY & PHARMACY | INHIBITOR | Tyrosine | Renal function | Hemodialysis | Drug interactions | Impairment | Clinical trials | Breast cancer | Pharmacology | Kinases | Drug interaction | Dialysis | Kidney diseases | Pharmacokinetics | Protein-tyrosine kinase | Drug dosages | Index Medicus
Journal Article
Journal Article